Clinical Trials in Papatoetoe, Auckland

Find clinical trials in Papatoetoe, Auckland. Discover local research opportunities and treatment options in your area.

5 Active Trials Found in Papatoetoe

Showing 5 trials on this page

Page 1 of 1

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT ID: NCT06632444

The LIVERAGE™ clinical trial is studying a medication called survodutide to see if it can help adults with a liver disease known as Metabolic Dysfunction Associated Steatohepatitis (MASH) who also ...

Recruiting

Phase: PHASE3 Conditions: Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT ID: NCT06632457

The LIVERAGE™ study is researching whether a medication called survodutide can help adults with a liver disease known as non-alcoholic steatohepatitis (NASH) or metabolic-associated steatohepatitis...

Recruiting

Phase: PHASE3 Conditions: Metabolic Dysfunction Associated Steatohepatitis

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT ID: NCT05843643

This clinical trial is studying the safety and effectiveness of a medication called upadacitinib for adults with moderate to severe systemic lupus erythematosus (SLE), a disease that causes inflamm...

Recruiting

Phase: PHASE3 Conditions: Systemic Lupus Erythematosus

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT ID: NCT05254743

This clinical trial is comparing two medications, pirtobrutinib (also known as LOXO-305) and ibrutinib, to see which one is more effective and safer for people with Chronic Lymphocytic Leukemia (CL...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma +2 more

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT ID: NCT03229200

This is a long-term, open-label study to keep giving ibrutinib to people who have benefited from it in previous trials but don’t have access to the drug in their region. It’s a single-group, Phase ...

Enrolling by invitation

Phase: PHASE4 Conditions: Solid Tumor, Lymphoma, Non-Hodgkin +3 more